TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
NTLA

Intellia Therapeutics Inc

Healthcare · Biotechnology

12.20$ -1.4% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow NTLA
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– -29.2% 219.1% -249.9% -201.3% -239.5% -86.1% -680.8% -639.4% -1,086.4% -602.8% -515.6%
– 5.4% 6.7% 11.5% 14.7% 13.0% 10.9% 20.8% 14.5% 24.7% 17.8% 15.2%
– 21.6% 40.7% 58.7% 56.0% 35.0% 34.3% 142.2% 175.4% 369.5% 266.6% 228.0%
– 21.8% 40.8% 59.3% 56.3% 35.0% 34.4% 138.2% 329.6% – – –
– 165.5% 363.6% -62.1% 10.4% -47.9% 99.2% -69.3% -103.4% -144.6% 20.5% -109.0%
– 42.3% 37.4% 38.6% 20.9% 15.8% 6.2% 38.6% 112.0% 38.6% 10.0% 8.5%
– -42.3% -37.4% -38.6% -856.9% 58.4% -369.8% -1,666.3% 307.6% -86.4% 217.0% 185.6%
– – 0.0% 0.0% – – – – – – – –
– -44.2% -0.6% 547.5% 132.1% 177.3% 641.1% 5,630.4% 1,118.5% – – –
– 1,162.9% 1,015.3% 547.5% 132.1% 177.3% 641.1% 2,228.8% 1,118.5% 359.3% 320.9% 274.5%
– 1,091.5% 1,197.0% 258.9% -926.0% -3.8% 185.2% -118.4% 786.6% -813.5% -64.9% -55.5%
– -71.4% 181.7% -288.6% -222.2% -255.3% -92.2% -719.4% -751.5% -1,124.9% -612.8% -524.1%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?